RASA DELETRAIN: Open Payments
NPI 1114695293 · CAPE CORAL, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$589 in 5 payments from 5 companies in 2025. Trend: 2023 $7 · 2024 $103 · 2025 $589
Food & beverage: $589
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 1 | $140 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $120 |
| Novo Nordisk Inc | 1 | $120 |
| Biogen, Inc. | 1 | $120 |
| Boston Scientific Corporation | 1 | $89 |
Products named: Veozah, CAPLYTA, Ozempic, ZURZUVAE, Axonics.
Industry payments across FL — which companies pay providers there.
